Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

The imperative of overcoming barriers to the conduct of large, simple trials.

Eapen ZJ, Lauer MS, Temple RJ.

JAMA. 2014 Apr 9;311(14):1397-8. doi: 10.1001/jama.2014.1030. No abstract available.

PMID:
24715072
2.

An oncoethical issue.

Cheson BD.

Clin Adv Hematol Oncol. 2006 Apr;4(4):241. No abstract available.

PMID:
16779896
3.

Issues of study design and data analysis.

D'Agostino RB.

Inflamm Bowel Dis. 1998 May;4(2):109-111; discussion 111-3. No abstract available.

PMID:
9687216
4.

Implications of an alternative approach to dose-response trials.

Sheiner LB.

J Acquir Immune Defic Syndr. 1990;3 Suppl 2:S20-6. No abstract available.

PMID:
2231298
5.

The Emergence of the Randomized, Controlled Trial.

Bothwell LE, Podolsky SH.

N Engl J Med. 2016 Aug 11;375(6):501-4. doi: 10.1056/NEJMp1604635. No abstract available.

6.

Cluster randomized trials: opportunities and barriers identified by leaders of eight health plans.

Mazor KM, Sabin JE, Boudreau D, Goodman MJ, Gurwitz JH, Herrinton LJ, Raebel MA, Roblin D, Smith DH, Meterko V, Platt R.

Med Care. 2007 Oct;45(10 Supl 2):S29-37.

PMID:
17909379
7.

Experimental and observational data and formulary listing.

Frear RS.

Value Health. 2010 Jun;13 Suppl 1:S26-9. doi: 10.1111/j.1524-4733.2010.00752.x. No abstract available.

8.
9.

Large streamlined trials in cardiovascular disease.

Calvo G, McMurray JJ, Granger CB, Alonso-García Á, Armstrong P, Flather M, Gómez-Outes A, Pocock S, Stockbridge N, Svensson A, Van de Werf F.

Eur Heart J. 2014 Mar;35(9):544-8. doi: 10.1093/eurheartj/eht535. Epub 2014 Jan 2. No abstract available.

PMID:
24385376
10.

Some observations on the collection of medical event data.

Mohberg NR.

Drug Inf J. 1987;21(1):55-62.

PMID:
10301497
11.

Regulatory perspectives on data monitoring.

O'Neill RT.

Stat Med. 2002 Oct 15;21(19):2831-42.

PMID:
12325099
12.

Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop.

Coffey CS, Levin B, Clark C, Timmerman C, Wittes J, Gilbert P, Harris S.

Clin Trials. 2012 Dec;9(6):671-80. doi: 10.1177/1740774512461859.

PMID:
23250942
13.

Overhauling clinical trials.

Scott CT, Baker M.

Nat Biotechnol. 2007 Mar;25(3):287-92. No abstract available.

PMID:
17344876
14.

The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT.

Emery S, Abrams DI, Cooper DA, Darbyshire JH, Lane HC, Lundgren JD, Neaton JD; ESPRIT Study Group..

Control Clin Trials. 2002 Apr;23(2):198-220.

PMID:
11943448
15.

[Randomized trials stopped early for benefit: is it good or bad?].

Candia B R, Letelier S LM, Rada G G.

Rev Med Chil. 2006 Nov;134(11):1470-5. Spanish. No abstract available.

PMID:
17679173
16.

Overcoming the funding challenge: the cost of randomized controlled trials in the next decade.

Shore BJ, Nasreddine AY, Kocher MS.

J Bone Joint Surg Am. 2012 Jul 18;94 Suppl 1:101-6. doi: 10.2106/JBJS.L.00193.

PMID:
22810458
17.

[Study designs for the evaluation of drug effects].

Christensen S, Christiansen CF, Sørensen HT.

Ugeskr Laeger. 2009 Mar 2;171(10):799-802. Danish.

PMID:
19265605
18.

Efficient use of endpoints in clinical trials: a clinical perspective.

Terrin ML.

Stat Med. 1990 Jan-Feb;9(1-2):155-60.

PMID:
2111931
19.

[The probe methodology can be considered an alternative to randomized double-blind?].

Dainesi SM.

Rev Assoc Med Bras (1992). 2010 Mar-Apr;56(2):132. Portuguese. No abstract available.

20.

[Clinical drug testing in the United States].

Engelbart S.

Fortschr Med. 1983 Jun 9;101(22):1021-2, 1049. German. No abstract available.

PMID:
6347848

Supplemental Content

Support Center